Reanna Gibbs
Medical · Mullica Hill, NJNPI 1497128920
Payments from drug & device makers
Across 187 payments — averaging $17.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- GSK$821
- Novo Nordisk$431
- Pfizer$276
- AstraZeneca$239
- Biohaven Pharmaceutical Holding Company Ltd.$149
- plus $287 from 9 others
What the payments were for
- Food & beverage$3,349100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 65 | $1,147 |
| GSK | 32 | $821 |
| Novo Nordisk | 28 | $431 |
| Pfizer | 20 | $276 |
| AstraZeneca | 14 | $239 |
| Biohaven Pharmaceutical Holding Company Ltd. | 12 | $149 |
| Novartis | 5 | $78 |
| Teva Pharmaceuticals USA, Inc. | 1 | $41 |
| Shield Therapeutics Inc | 2 | $36 |
| Intuity Medical Inc | 2 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $25 |
| Exact Sciences | 1 | $22 |
| ANI Pharmaceuticals, Inc. | 1 | $21 |
| Acella Pharmaceuticals, LLC | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,349 in reported general payments places this provider in the 80th percentile of 573 medical providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 16 | $27,942 |
| EliquisApixaban | 28 | $23,262 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $22,618 |
| FarxigaDapagliflozin Propanediol | 22 | $20,004 |
| Morphine Sulfate ErMorphine Sulfate | 25 | $814 |
| Atorvastatin Calcium | 62 | $681 |
| Levothyroxine Sodium | 79 | $671 |
| Gabapentin | 44 | $487 |
| Omeprazole | 32 | $486 |
| Amlodipine Besylate | 51 | $451 |
| Pregabalin | 18 | $427 |
| Lisinopril | 86 | $375 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 18 | $354 |
| Tamsulosin Hcl | 24 | $345 |
| Metformin Hcl | 69 | $342 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $431 | $27,94216 claims |
| PfizerEliquis | $276 | $23,26228 claims |
| GSKTrelegy Ellipta | $821 | $22,61822 claims |
| AstraZenecaFarxiga | $239 | $20,00422 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 573 medical providers in New Jersey.
Other medical in Mullica Hill
- Alison PietrasBrick$1.2M
- Shannon WelnerVerona$176K
- Christinna DelgenioColts Neck$114K
- Anita FoxVerona$17K
- Therese CasasKinnelon$16K
- Joseph CollettiLinwood$16K
- Melissa MiaoKearny$14K
- Gabriela Plesek-AndiaVerona$13K
- Stephanie PhillipsMarlton$12K
- Sean AdairCape May Court House$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.